Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2005

01-07-2005 | Brief Communication

Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides

Authors: Elizabeth A. Mittendorf, Catherine E. Storrer, Craig D. Shriver, Sathibalan Ponniah, George E. Peoples

Published in: Breast Cancer Research and Treatment | Issue 1/2005

Login to get access
Metadata
Title
Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides
Authors
Elizabeth A. Mittendorf
Catherine E. Storrer
Craig D. Shriver
Sathibalan Ponniah
George E. Peoples
Publication date
01-07-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-0988-1

Other articles of this Issue 1/2005

Breast Cancer Research and Treatment 1/2005 Go to the issue

OriginalPaper

Extracorporeal high intensity focused ultrasound treatment for patients with breast cancer

Report

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

Brief Communication

No adverse effects of adjuvant chemotherapy on hippocampal volumein Japanese breast cancer survivors

Letter to the editor

Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?

Report

Radiological and surgical placement of port devices: a 4-year institutional analysis of procedure performance, quality of life and cost in breast cancer patients

Clinical trial

Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits